First‐in‐human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS‐penetrant soluble guanylyl cyclase stimulator

Soluble guanylate cyclase (sGC) and its product, cyclic guanosine monophosphate, play a role in learning and memory formation. Zagociguat (CY6463) is a novel stimulator of sGC being developed for the treatment of neurodegenerative disease. Single zagociguat doses of 0.3, 1, 3, 10, 20, 30, and 50 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: van Kraaij, Sebastiaan J. W., Gal, Pim, Borghans, Laura G. J. M., Klaassen, Erica S., Dijkstra, Francis, Winrow, Christopher, Glasser, Chad, Groeneveld, Geert Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432884/
https://www.ncbi.nlm.nih.gov/pubmed/37118895
http://dx.doi.org/10.1111/cts.13537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432884/
https://www.ncbi.nlm.nih.gov/pubmed/37118895
http://dx.doi.org/10.1111/cts.13537

Ejemplares similares